Omniscient Neurotechnology

Omniscient Neurotechnology (o8t) develops brain mapping software and analytics platforms for clinicians and researchers working in neuroscience and brain health. The company applies artificial intelligence and cloud computing to connectomics — the construction and analysis of computer-generated maps of the brain's functional and structural connections — to help medical professionals make more informed decisions about diagnosis, surgical planning, and treatment across a range of neurological conditions.

Omniscient serves two primary audiences: neurosurgeons who require precise, patient-specific brain network data to guide surgical decisions, and researchers who need to process large volumes of neural data to extract structural and functional insights at the individual subject level. The company states its broader mission as improving the lives of billions through connectomics, with a focus on conditions including depression, Alzheimer's disease, schizophrenia, and stroke.

Core Platform

• Quicktome is Omniscient's AI-powered connectomic analysis platform, designed to provide clinicians with detailed insights into patient-specific brain networks and function.
• Quicktome automatically analyzes millions of data points derived from MRI and resting-state functional MRI (rs-fMRI) using AI-enabled post-processing.
• The platform generates an individualized roadmap intended to support the most appropriate approach for each patient.
• It provides insights relevant to cranial surgery, neuro-oncology, stroke, and other neurological conditions.
• Results are accessible directly through a web browser, without requiring deep technical knowledge from the end user.
• Reported processing times from clinical users indicate full image processing can be completed in under two hours, with less than five minutes of direct clinician intervention.

Technology and Methodology

• The workflow begins with MRI scans of a patient's brain, which are then processed in cloud-based software using proprietary algorithms.
• Users access the resulting brain maps and insights via a web browser, which can then inform personalized therapy planning.
• The platform draws on connectomics — described as a big data approach to mapping the brain's connections — as well as tractography, an imaging technique used to map white matter bundles and their constituent fibres.
• Brain network analysis is central to the approach, reflecting the understanding that human brain functions are governed by multiple areas working together rather than individual regions in isolation.
• AI and cloud computing are used to make these analyses scalable and accessible without requiring specialist technical infrastructure on the user's side.

Research and Intellectual Property

• Omniscient's research and development team collaborates with institutions globally to advance brain analytics.
• The company reports 93 publications, 301 citations, and 37 patents issued by the USPTO.
• Research activity is focused on deepening understanding of brain complexity and expanding the possibilities for treating and preventing neurological conditions.

Clinical Adoption and User Feedback

• Neurosurgeons from institutions including Macquarie University Hospital (Sydney, Australia), University of Miami Hospital, Miami Neuroscience Institute, and WVU Medicine Berkley Medical Center have publicly commented on the platform.
• Cited benefits include the ability to localize pathology, preserve function during tumor removal, reduce manual tractography workload, and access an advanced yet user-friendly interface.
• The platform has been described by clinical users as a significant step forward in understanding brain function and interconnections.

Leadership and Team

• Dr. Michael Sughrue, Co-Founder and Chief Medical Officer, built one of the largest neurosurgery practices in the United States and contributes clinical expertise to the company's product development.
• Dr. Stephane Doyen, Co-Founder and Chief Data Scientist, previously served as head of Data Science at Oliver Wyman and brings expertise in machine learning and technical leadership.
• Stephen Scheeler, CEO and Managing Director, previously led Facebook's Australia and New Zealand operations and brings software business leadership to the company.
• The broader team combines data scientists, engineers, and health technology professionals.

Omniscient partners with a number of research and clinical institutions and positions its technology across the full continuum of neurological care, from pre-surgical planning through to research into conditions that have historically been difficult to diagnose or treat.